NCT05971940

A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 559 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The study will last approximately 54 weeks.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Orforglipron	Administered orally.
DRUG	Placebo	Administered orally

Timeline

• Start date: 2023-08-09
• Primary completion: 2025-04-03
• Completion: 2025-04-03
• First posted: 2023-08-02
• Last updated: 2025-04-23

Locations

89 sites across 6 countries: United States, China, India, Japan, Mexico, Puerto Rico

Regulatory

• FDA-regulated drug study